Advanced Life Sciences, Inc. (ADLS) Submits Lead Drug as New Treatment for Pneumonia
Advanced Life Sciences, Inc. (NASDAQ:ADLS), an Illinois based biopharmaceutical company, today announced submission of a new drug application (NDA) for its lead product, cethromycin, a unique once-a-day antibiotic for respiratory tract infections. The NDA submission is for cethromycin in mild-to-moderate community-acquired pneumonia (CAP). Community-acquired pneumonia is the sixth most common cause of death in the U.S., affecting 5.6 million Americans annually. The company is focusing its resources on the development and commercialization of cethromycin for use in respiratory tract infections such as community-acquired pneumonia, bronchitis, and sinusitis. Penicillins and macrolides are currently the most common treatment for CAP, but increasing…